The US approves Revolution's drug that doubles survival in pancreatic cancer
The FDA, the US drug regulator, approves Revolution Medicines' Rasonque pill, under an accelerated review process.
The US FDA has approved Revolution Medicines' pill Rasonque for pancreatic cancer through an accelerated review process. The daily pill is for metastatic pancreatic cancer patients who have received previous treatment or cannot receive combined chemotherapy. Rasonque blocks several forms of the RAS protein, which contributes to tumor growth in many pancreatic cancer types.
The drug is now available in the US at $39,800 for a 30-day supply. Revolution Medicines' shares have risen over 170% this year, with analysts estimating Rasonque could generate $11.5 billion in annual global sales.
Written by urgent.news from Expansion ES's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
